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1. BACKGROUND {#pedi12870-sec-0001}
=============

The primary prevention of common chronic disease is a major public health goal. Type 1 diabetes (T1D) is among the more frequent chronic diseases in childhood, and is increasing in incidence.[1](#pedi12870-bib-0001){ref-type="ref"} T1D results from an immune‐mediated destruction of pancreatic islet beta‐cells resulting in insulin deficiency. This process is identified by circulating autoantibodies to beta‐cell antigens, indicative of a break in immunological self‐tolerance.[2](#pedi12870-bib-0002){ref-type="ref"}, [3](#pedi12870-bib-0003){ref-type="ref"} Neonates or infants who are at increased genetic risk for multiple beta‐cell autoantibodies and T1D can be identified using genetic markers and T1D family history.[4](#pedi12870-bib-0004){ref-type="ref"} Risk stratification by such genetic markers is now sufficiently advanced to bring testing to a population‐based level and, thereby, facilitates the primary prevention of beta‐cell autoimmunity and T1D.[5](#pedi12870-bib-0005){ref-type="ref"}

Primary prevention of T1D has a strong rationale. There is a clear peak incidence period of beta‐cell autoantibody seroconversion between age 9 months and 3 years demonstrated in German,[6](#pedi12870-bib-0006){ref-type="ref"} Finnish,[7](#pedi12870-bib-0007){ref-type="ref"} and The Environmental Determinants of Diabetes in the young (TEDDY) studies.[8](#pedi12870-bib-0008){ref-type="ref"} This provides a convenient study follow‐up time in order to execute controlled clinical trials. Insulin is a first autoantibody target.[6](#pedi12870-bib-0006){ref-type="ref"}, [8](#pedi12870-bib-0008){ref-type="ref"}, [9](#pedi12870-bib-0009){ref-type="ref"} It is widely held that if infant tolerance to beta‐cell autoantigens could be enhanced, this could prevent or delay the onset of pre‐ or asymptomatic T1D (defined as loss of tolerance and multiple beta‐cell autoantibodies), and hence prevent or delay the clinical onset of diabetes.[10](#pedi12870-bib-0010){ref-type="ref"} As a primary prevention, we have laid the foundation for autoantigen‐specific tolerance induction initiated prior to an autoimmune memory response. We have identified a dose of insulin that when administered orally on a daily basis to beta‐cell autoantibody negative children at increased genetic risk is safe (neither affecting plasma glucose levels nor causing an allergic reaction) and appears to engage the immune system in a manner that is consistent with immune‐mediated, tolerogenic protection.[11](#pedi12870-bib-0011){ref-type="ref"} Therefore, the task is now to identify neonates or infants at increased genetic risk for T1D to execute the first insulin‐based primary prevention trial. The objective of the Global Platform for the Prevention of Autoimmune Diabetes (GPPAD)‐02 study protocol is to identify neonates or infants who have \>10% risk for developing multiple beta‐cell autoantibodies by the age of 6 years, which is the risk we have defined as the requirement for participation in a primary prevention randomized controlled trial that tests the effects of daily oral insulin vs placebo on the incidence of beta‐cell autoantibody seroconversion. GPPAD will continue and likely improve screening for future primary prevention clinical trials.

2. STUDY ORGANIZATION {#pedi12870-sec-0002}
=====================

GPPAD is a network of collaborating investigators from seven clinical trial centers located in five European countries: Germany (Bavaria, Saxony, Lower Saxony); UK (Oxford); Poland (Warsaw); Belgium (Leuven), and Sweden (Region Skåne). GPPAD was created to allow a multidisciplinary approach to prevent T1D and is coordinated by a GPPAD coordinating center in Germany (Munich).

2.1. Identification of high genetic risk for T1D {#pedi12870-sec-0003}
------------------------------------------------

T1D has a multifactorial etiology, which is determined by genetic and environmental factors.[3](#pedi12870-bib-0003){ref-type="ref"} Lifetime risk in a European population is around 0.4%. A first‐degree family history of T1D is associated with a 5% risk for T1D.[4](#pedi12870-bib-0004){ref-type="ref"} There are at least 50 regions of the genome where genetic variation is associated with T1D risk,[12](#pedi12870-bib-0012){ref-type="ref"} the most important of these being in the HLA DR‐DQ region of chromosome 6. Certain HLA DR‐DQ genotypes confer markedly elevated risk for T1D. Notably, infants who are first‐degree relatives of patients and who have the HLA DR4‐DQ8 haplotype, and infants who have either the HLA DR3/DR4‐DQ8 or the DR4‐DQ8/DR4‐DQ8 genotype have a risk of around 5%.[4](#pedi12870-bib-0004){ref-type="ref"}, [13](#pedi12870-bib-0013){ref-type="ref"} Typing at additional T1D susceptibility regions can identify neonates or infants with risks that are 10% or more.[5](#pedi12870-bib-0005){ref-type="ref"} We have recently developed a T1D genetic score that identified neonates or infants without family history of T1D who had a greater than 10% risk for pre‐symptomatic T1D, and a nearly 2‐fold higher risk than children identified by high‐risk HLA genotypes alone. Thus, family history and genetic markers can be used to identify neonates or infants with 25‐fold increased risk for T1D.[5](#pedi12870-bib-0005){ref-type="ref"} Genetic risk in GPPAD‐02 is based on these newly developed risk scores derived from a total of 46 single‐nucleotide polymorphisms (SNPs) including SNPs that define HLA DR3, HLA DR4, and HLA DQ8 alleles as well as SNPs from HLA class I and non‐HLA T1D susceptibility genes, and from HLA class II protective alleles ([Supplemental Table 1](#pedi12870-supitem-0001){ref-type="supplementary-material"}).

3. STUDY PROCEDURES {#pedi12870-sec-0004}
===================

3.1. Testing for T1D risk {#pedi12870-sec-0005}
-------------------------

Newborn screening for genetic, endocrine, and metabolic disorders is routinely done within the first days after birth at obstetric clinics or pediatrician offices, using a few drops of blood from the heel onto filter paper cards, or venous blood taken from the back of the hand. Testing for T1D risk is offered to families together with the regular newborn screening as a supplemental test with separate consent (Belgium, Germany, Poland, UK). Alternatively, it is offered at delivery using cord blood (Sweden) or at a pediatric visit before the age of 5 months (Sweden, Germany). At least one and a maximum of two blood spots are collected for testing of T1D risk using a separate GPPAD‐02 filter paper card (Belgium, Germany, Sweden) or using the newborn screening filter paper card (UK, Poland). The dried blood spot filter paper cards are sent to the specialized newborn screening laboratories or the local clinical study center for subsequent retrieval. The screening target is 330 000 newborns or infants prior to age of 5 months.

3.2. Consent procedure {#pedi12870-sec-0006}
----------------------

Parents or legal guardians of neonates or infants are asked whether they wish to participate in the study. A qualified physician, midwife, or study nurse performs the informed consent in accordance with country‐specific guidelines and ethical review board requirements, providing written and verbal information explaining the objectives of the GPPAD‐02 study and the opportunities of primary prevention and follow‐up for infants with high genetic risk. The families are told that if their child is found to have a high risk for T1D, they will be contacted and offered the possibility of participation in the prevention study with further informed consent. In Sweden, additional information on a clinical trial aiming to prevent celiac disease is given to children with intermediate risk for T1D and risk for celiac disease is also provided.

Parents or guardians are given sufficient time to read the informed consent material and have any questions answered. It is explained that participation in the project is voluntary and that consent can be withdrawn at any time without providing a reason and without disadvantages by doing so. Confidentiality and protection of the data of every participant is maintained throughout the entire study. Only the local study personnel have access to personal identifiers. The informed consent form must be signed and dated by at least one parent/guardian. The parent or guardian is given a copy of the informed consent.

3.3. Demographic data {#pedi12870-sec-0007}
---------------------

Name, contact information of the parents, child\'s date of birth, gender, weight, date of blood collection, mother\'s date of birth, first‐degree family history of T1D are collected either by a separate questionnaire or by extracting the information from the regular newborn screening card. Only pseudonymized data are entered into a central database held at the GPPAD coordinating center, Helmholtz Zentrum Muenchen, Germany.

3.4. Genetic testing {#pedi12870-sec-0008}
--------------------

DNA is extracted from a 3.2‐mm punch of one dried blood spot and tested for the 46 SNPs ([Supplemental Table 1](#pedi12870-supitem-0001){ref-type="supplementary-material"}). DNA extraction and SNP typing are performed in a central genotyping lab (LGC group, TEDDINGTON, Middlesex, UK \[<https://www.lgcgroup.com>\]; Figure [1](#pedi12870-fig-0001){ref-type="fig"}A).

![(A) GPPAD‐02 study design and (B) Definition of increased genetic risk](PEDI-20-720-g001){#pedi12870-fig-0001}

For sites where extra blood spots are collected for the GPPAD study (Germany, Sweden, Belgium), the remainder of the card is kept with the local GPPAD‐02 team for at least 3 months in case repeat testing is required. Thereafter, the card is destroyed or, if there is consent for it to be kept for further research, stored at −20°C or −80°C.

The genetic risk score is calculated as previously described,[7](#pedi12870-bib-0007){ref-type="ref"} by multiplying the number of risk alleles (ie, 0, 1 or 2 for each single SNP) with the weight assigned to each SNP ([Supplemental Table 1](#pedi12870-supitem-0001){ref-type="supplementary-material"}). The weighted contributions of all SNPs plus an additive constant for each of the two HLA class II categories: 3.15 for infants who have the HLA DR4‐DQ8/DR4‐DQ8 genotype, 3.98 for infants who have the HLA DR3/DR4‐DQ8 genotype, 3.12 for infants who have the HLA DR3/DR3 genotype, 2.08 for infants who have the HLA DR4‐DQ8/DRX genotype, 1.55 for infants who have the HLA DR3/DRX genotype are summed.

3.5. Definition of high genetic risk {#pedi12870-sec-0009}
------------------------------------

For neonates or infants without a first‐degree family history of T1D, high genetic risk is defined as a DR3/DR4‐DQ8 or DR4‐DQ8/DR4‐DQ8 genotype, and a high genetic risk score \>14.4. For neonates or infants with a first‐degree family history of T1D, high genetic risk is defined as having HLA DR4 and DQ8, and none of the protective alleles DRB1\*1501 (SNP tag rs3129889) or DQB1\*0503 (SNP tag rs1794265). Neonates or infants identified with high genetic risk are expected to have \>10% risk for developing multiple beta‐cell autoantibodies by the age of 6 years.[9](#pedi12870-bib-0009){ref-type="ref"} The estimated prevalence of neonates or infants with this high risk for T1D is \~1% (Figure [1](#pedi12870-fig-0001){ref-type="fig"}B).

3.6. Result notification {#pedi12870-sec-0010}
------------------------

Families of infants with a high risk for T1D are contacted by phone by an experienced physician/pediatrician or trained nurse from the local GPPAD‐02 team. The family is invited to a face‐to‐face consultation at the clinical study center, or alternatively at the primary care pediatrician\'s office. Dependent on the site‐specific arrangements, the family may receive a result letter confirming the date of the consultation, and a brochure, which explains the meaning of T1D risk to the family, describes T1D symptoms, and informs about trials to prevent disease initiation and progression. The face‐to‐face consultation visit is planned to take place before 5 months of age and includes all parents/guardians. The content of the brochure may also be discussed during the consultation (Figure [1](#pedi12870-fig-0001){ref-type="fig"}A).

Families of children with an estimated risk that is less than 10% are not contacted unless there is a country‐specific follow‐up of children with intermediate risk of T1D or who have a high risk for celiac disease (Sweden), but are provided with a contact phone number if they want to inquire about the result.

3.7. Invitation to participate in prevention trial {#pedi12870-sec-0011}
--------------------------------------------------

Infants with high genetic risk for T1D are asked to participate in a randomized controlled trial aiming to prevent the initiation of beta‐cell autoimmunity and T1D (GPPAD‐03 POInT Trial; <http://clinicaltrials.gov> Identifier: NCT03364868). Families who decide not to participate in GPPAD‐03 (POInT) may be asked to participate in existing natural follow‐up studies aiming to prevent metabolic complications such as diabetic ketoacidosis through an early diagnosis of T1D program, and to investigate immunological alterations in the pathogenesis of the disease (ie, Fr1da in Bavaria, Fr1dolin in Lower Saxony). Participation in GPPAD‐03 (POInT) and Fr1da/Fr1dolin requires a separate consent (Figure [1](#pedi12870-fig-0001){ref-type="fig"}). In Sweden, subjects at intermediate risk for T1D and high risk for celiac disease are asked to participate in a prevention study of celiac disease (<http://clinicaltrials.gov> Identifier: NCT03562221).

3.8. Psychological assessment {#pedi12870-sec-0012}
-----------------------------

The psychological impact of the consultation in which the increased genetic risk for developing T1D is communicated is subsequently monitored using a standardized questionnaire (Patient Health Questionnaire) in Germany and Sweden. The questionnaire looks for evidence of depression, anxiety and burden, and is handed to the parents at the face‐to‐face consultation visit. A trained and experienced psychologist of the GPPAD‐02 team checks the questionnaire within 5 days. Families with elevated anxiety and depression levels (depression score \> 5) are referred for consultation to a psychologist. In general, the parents are offered to contact the free telephone GPPAD‐02‐hotline with any questions or concerns.

3.9. Statistical analyses {#pedi12870-sec-0013}
-------------------------

Analyses that are planned as part of the study will be limited to descriptive statistics. These will include the number of infants consented and tested per month per region and country, the frequency of infants with and without a first‐degree relative with T1D, the proportion of children with high genetic risk, the proportion of families attending the consultation visit, the proportion of families with increased depression or anxiety and the distribution of scores from the Patient Health Questionnaire, and the proportion of families consenting to participate in the GPPAD‐03 prevention trial.

Comparisons of the genetic risk score between the study centers were performed using Kruskal‐Wallis test, one‐way analysis of variance with *P*‐values corrected by the Bonferroni adjustment and the comparison between boys and girls was performed using the Mann‐Whitney *U* test.

4. DATA SHARING {#pedi12870-sec-0014}
===============

GPPAD is committed to open data sharing in compliance with all applicable European and GPPAD Consortium Member State, Data Protection and Privacy Protection laws, rules and regulations to facilitate scientific progress and patient benefit. GPPAD makes anonymized data of GPPAD‐02 available to the scientific community on a regular basis (<https://www.gppad.org/en/data-sharing/>).

5. PRELIMINARY RESULTS {#pedi12870-sec-0015}
======================

From October 2017 to December 2018, 50 669 infants, including 891 (1.76%) with a first‐degree family history of T1D (FDR), have been screened for increased genetic risk of T1D (Figure [2](#pedi12870-fig-0002){ref-type="fig"}). The T1D‐associated HLA risk genotypes DR3/DR4‐DQ8 or DR4‐DQ8/DR4‐DQ8 were present in 1263 (2.5%) children from the general population and the HLA DR4‐DQ8 haplotype was present in 250 (28.1%) FDR children (Table [1](#pedi12870-tbl-0001){ref-type="table"}). Among the general population children with HLA DR3/DR4‐DQ8 or DR4‐DQ8/DR4‐DQ8 genotypes, 327 (0.7% of all screened) children had a genetic risk score \>14.4 which is the threshold above which there is a \>10% risk for developing multiple beta‐cell autoantibodies by the age of 6 years. Of the remainder, 631 (1.3% of all screened) children had a genetic risk score between 13.1 and 14.4, and 305 (0.6% or all screened) a genetic risk score below 13.1. In FDR children, 250 (28.1%) of 891 had a HLA DR4‐DQ8 haplotype and no protective allele associated with \>10% risk to develop multiple beta‐cell autoantibodies by the age of 6 years (Table [1](#pedi12870-tbl-0001){ref-type="table"}). The minor allele frequency of each SNP and the median genetic risk score are provided in Table [2](#pedi12870-tbl-0002){ref-type="table"}. The median genetic risk score of all children was 10.59 (IQR: 9.76‐11.62) and of the eligible infants was 14.55 (IQR: 12.98‐15.02). The genetic risk score of screened children was higher in Sweden (Region Skåne) (median: 10.96, IQR: 9.86‐11.99, *P* \< .01) and lower in Leuven, Belgium (median: 10.22, IQR: 9.59‐11.18, *P* \< .01) when compared to the other study centers and was not significantly different between male (median: 10.59, IQR: 9.76‐11.64) and females (median: 10.58, IQR: 9.75‐11.61; *P* = .43).

![Cumulative number of newborns/infants screened in the GPPAD‐02 study. Numbers are shown from the start of the study in October 2017. The red line represents the expected numbers and the blue line shows the actual number of screened infants](PEDI-20-720-g002){#pedi12870-fig-0002}

###### 

First results from population‐based screening for type 1 diabetes genetic risk (GPPAD‐02)

                                                        General population                                                    
  ----------------------------------------------------- -------------------- ------------ ------------ ----------- ---------- -----------
  Total screened                                        49 778               34 677       12 971       448         344        1338
  HLA DR3/DR4‐DQ8 or DR4‐DQ8/DR4‐DQ8                    1263 (2.5%)          885 (2.6%)   300 (2.3%)   29 (6.5%)   3 (0.9%)   46 (3.4%)
  Risk score in HLA DR3/DR4‐DQ8 or DR4‐DQ8/DR4‐DQ8                                                                            
  \<13.1                                                305 (0.6%)           214 (0.6%)   73 (0.6%)    5 (1.1%)    1 (0.3%)   12 (0.9%)
  13.1‐14.4                                             631 (1.3%)           447 (1.3%)   146 (1.1%)   15 (3.4%)   2 (0.6%)   21 (1.6%)
  \>14.4[a](#pedi12870-note-0001){ref-type="fn"}        327 (0.7%)           224 (0.7%)   81 (0.6%)    9 (2.0%)    0 (0%)     13 (1.0%)
  HLA DR3/DR3[b](#pedi12870-note-0002){ref-type="fn"}   557 (1.1%)           354 (1.0%)   160 (1.2%)   11 (2.5%)   3 (0.9%)   29 (2.2%)

                                                                                        First‐degree relatives                                                      
  ------------------------------------------------------------------------------------- ------------------------ ------------- ------------ ----------- ----------- ------------
  Total screened                                                                        891                      709           149          20          5           8
  HLA DR4‐DQ8 and no DRB1\*1501 or DQB1\*0503[a](#pedi12870-note-0001){ref-type="fn"}   250 (28.1%)              195 (27.5%)   38 (25.5%)   8 (40.0%)   1 (20.0%)   8 (100.0%)

Eligible for POInT Trial (GPPAD‐03).

High risk for celiac disease.

###### 

Minor allele frequency of each SNP and the median genetic risk score

  SNP                           Gene              Minor allele frequency                                           
  ----------------------------- ----------------- ------------------------ ------- ------- ------- ------- ------- -------
  rs17426593                    DR4               0.135                    0.151   0.132   0.216   0.137   0.175   0.112
  rs2187668                     DR3               0.100                    0.115   0.102   0.12    0.101   0.131   0.106
  rs7454108                     DQ8               0.090                    0.099   0.075   0.14    0.090   0.091   0.079
  rs3129889                     *DRB1*\*1501      0.125                    0.121   0.091   0.127   0.121   0.114   0.121
  rs1794265                     *DQB1*\*0503      0.025                    0.034   0.031   0.024   0.032   0.030   0.021
  rs1264813                     HLA A 24          0.120                    0.124   0.110   0.108   0.126   0.101   0.116
  rs2395029                     HLA B 5701        0.035                    0.033   0.035   0.032   0.032   0.035   0.035
  rs2476601                     *PTPN22*          0.108                    0.093   0.068   0.112   0.092   0.088   0.130
  rs2816316                     *RGS1*            0.178                    0.181   0.195   0.198   0.177   0.180   0.182
  rs3024505                     *IL10*            0.164                    0.166   0.140   0.154   0.161   0.145   0.168
  rs1990760                     *IFIH1*           0.385                    0.405   0.399   0.376   0.402   0.424   0.354
  rs3087243                     *CTLA4*           0.425                    0.444   0.451   0.412   0.437   0.459   0.369
  rs10517086                    *C4orf52*         0.283                    0.287   0.293   0.278   0.286   0.279   0.285
  rs2069763                     *IL2*             0.360                    0.350   0.305   0.397   0.338   0.318   0.357
  rs6897932                     *IL7R*            0.246                    0.250   0.277   0.290   0.243   0.248   0.254
  rs3757247                     *BACH2*           0.447                    0.450   0.425   0.412   0.456   0.457   0.447
  rs9388489                     *C6orf173*        0.466                    0.479   0.483   0.461   0.481   0.486   0.444
  rs6920220                     *TNFAIP3*         0.187                    0.195   0.163   0.229   0.183   0.204   0.165
  rs1738074                     *TAGAP*           0.383                    0.389   0.451   0.425   0.393   0.445   0.344
  rs7804356                     *SCAP2*           0.225                    0.234   0.244   0.231   0.230   0.231   0.189
  rs4948088                     *COBL*            0.042                    0.040   0.038   0.044   0.038   0.042   0.038
  rs7020673                     *GLIS3*           0.469                    0.468   0.439   0.496   0.465   0.471   0.468
  rs12722495                    *IL2RA*           0.100                    0.094   0.074   0.099   0.099   0.084   0.092
  rs947474                      *PRKCQ*           0.194                    0.199   0.194   0.168   0.195   0.197   0.191
  rs10509540                    *RNLS/C10orf59*   0.267                    0.267   0.267   0.302   0.267   0.259   0.266
  rs1004446                     *INS*             0.357                    0.358   0.385   0.332   0.350   0.380   0.351
  rs4763879                     *CD69*            0.381                    0.364   0.332   0.370   0.368   0.355   0.380
  rs2292239                     *ERBB3*           0.309                    0.305   0.275   0.341   0.309   0.324   0.300
  rs3184504                     *SH2B3*           0.496                    0.477   0.442   0.448   0.483   0.403   0.496
  rs1465788                     *ZFP36L1*         0.265                    0.272   0.244   0.258   0.267   0.282   0.257
  rs17574546                    *RASGRP1*         0.180                    0.177   0.166   0.198   0.180   0.179   0.176
  rs3825932                     *CTSH*            0.327                    0.327   0.373   0.326   0.332   0.362   0.312
  rs12708716                    *CLEC16A*         0.357                    0.345   0.387   0.324   0.367   0.364   0.345
  rs4788084                     *IL27*            0.442                    0.417   0.383   0.435   0.411   0.390   0.472
  rs7202877                     *CTRB2*           0.116                    0.100   0.093   0.126   0.106   0.091   0.127
  rs2290400                     *ORMDL3*          0.494                    0.489   0.448   0.463   0.488   0.491   0.468
  rs7221109                     *CCR7*            0.406                    0.384   0.368   0.387   0.405   0.354   0.434
  rs45450798                    *PTPN2*           0.149                    0.147   0.159   0.145   0.144   0.157   0.138
  rs763361                      *CD226*           0.482                    0.477   0.500   0.480   0.488   0.499   0.444
  rs425105                      *PRKD2*           0.160                    0.156   0.136   0.150   0.159   0.173   0.172
  rs2281808                     *SIRPG*           0.327                    0.313   0.316   0.324   0.319   0.318   0.333
  rs3788013                     *UBASH3a*         0.410                    0.409   0.386   0.418   0.412   0.423   0.388
  rs5753037                     *RPS3AP51*        0.353                    0.361   0.366   0.361   0.353   0.339   0.324
  rs229541                      *IL2B*            0.423                    0.425   0.430   0.413   0.432   0.451   0.400
  rs5979785                     *TLR8*            0.266                    0.287   0.296   0.263   0.283   0.299   0.232
  rs2664170                     *GAB3*            0.307                    0.318   0.346   0.307   0.307   0.339   0.307
  Genetic risk score (median)   10.58             10.65                    10.22   10.96   10.54   10.56   10.57   

Abbreviation: SNPs, single‐nucleotide polymorphisms.

6. SIGNIFICANCE AND NOVELTY {#pedi12870-sec-0016}
===========================

The GPPAD‐02 study will provide a unique population‐based path to primary prevention of beta‐cell autoimmunity. Participation in GPPAD‐02 also provides a platform to enable assessment of interventions for secondary prevention of T1D if children develop beta‐cell autoantibodies in the course of the prevention or during natural follow‐up. GPPAD and the GPPAD‐02 study will, therefore, closely collaborate with INNODIA (<http://www.innodia.eu>), TrialNet (<http://www.diabetestrialnet.org>), and others for such opportunities. The eventual benefit to the community, if successful, will be a reduction in the number of children developing T1D.

Supporting information
======================

###### 

**Supplemental Table 1** List of SNPs determined GPPAD‐02 and risk score calculation.

###### 

Click here for additional data file.
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